Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2019

GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2019 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30, 2019 to August 15, 2019 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First Quarter ended June 30, 2019.
31-07-2019
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholding for the Period Ended June 30, 2019

Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here
16-07-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Statement Of Investor Complaints For The Quarter Ended June 2019

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 011110 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer
15-07-2019
Bigul

Torrent Pharma joins hands with Glenmark to co-market diabetes drug

About two months after launching novel anti-diabetic drug Remogliflozin etabonate (Remogliflozin) in India, global drug firm Glenmark Pharmaceuticals
11-07-2019
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating

Glenmark would like to inform you that Fitch Ratings, as part of their annual review cycle, has reaffirmed the Company's credit rating at 'BB', outlook 'stable'. This credit rating assigned to Glenmark is much higher than some of its global peers as mentioned in the enclosed report. The agency also affirmed the rating on Company's USD200 million 4.50% senior unsecured notes issued in 2016 at ''BB''. Kindly find enclosed rating research update issued by Fitch Ratings for your reference.
11-07-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Glenmark & Torrent sign licensing agreement for co-marketing of Remogliflozin Etabonate in India
11-07-2019
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg
09-07-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg
09-07-2019
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions on a consolidated basis drawn in accordance with the relevant accounting standards. The said disclosure has also been published on the website of the Company. Kindly consider same in your records.
28-06-2019
Bigul

Glenmark Pharma gets USFDA nod for cholesterol lowering drug

Glenmark Pharmaceuticals on Friday said it has received final approval from the US health regulator for Ezetimibe and Simvastatin tablets, used for t
28-06-2019
Next Page
Close

Let's Open Free Demat Account